Verona Pharma plc
VRNA
Helyezés a részvények között
#2235
Verona Pharma plc is a biopharmaceutical company currently in its clinical... Verona Pharma plc is a biopharmaceutical company currently in its clinical development phase, focusing on the research, development, and eventual market launch of new therapies for respiratory illnesses where current treatments are inadequate. Its primary experimental medication is ensifentrine, an inhaled compound designed to simultaneously block both phosphodiesterase (PDE) 3 and PDE4 enzymes. This unique mechanism allows it to function both as a bronchodilator, helping to open the airways, and as an anti-inflammatory agent within a single drug. Ensifentrine is presently undergoing advanced (Phase 3) clinical trials to evaluate its effectiveness in treating chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. To provide versatile administration options, the company is developing ensifentrine in three distinct formulations: a nebulizer solution, a dry powder inhaler (DPI), and a pressurized metered-dose inhaler (pMDI). Verona Pharma plc was established in 2005 and conducts its operations from its headquarters in London, United Kingdom.
Részvényárfolyam
$106.91
Utolsó szinkronizálás: 2025-10-07
Piaci kapitalizáció
$9.09B
Változás (1 nap)
0.00%
Változás (1 év)
0.00%
Ország
GB
Kereskedés Verona Pharma plc (VRNA)
Kategória
Healthcare
Verona Pharma plc (VRNA) P/B aránya
P/B arány ekkor: October 2026 TTM: 41.96
Verona Pharma plc legfrissebb pénzügyi jelentései és részvényára alapján a vállalat jelenlegi könyv szerinti árfolyam aránya (P/B, TTM) 41.96. 2023 végén ez az arány 6.02 volt.
P/B arány története a(z) Verona Pharma plc esetén 2005 és 2026 között
P/B arány az év végén
| Év | P/B arány | Változtassa meg |
|---|---|---|
| 2026 (TTM) | 41.96 | 130.17% |
| 2024 | 18.23 | 202.67% |
| 2023 | 6.02 | -19.60% |
| 2022 | 7.49 | 178.89% |
| 2021 | 2.69 | 115.77% |
| 2020 | 1.24 | -3.18% |
| 2019 | 1.29 | 3.29% |
| 2018 | 1.24 | 34.11% |
| 2017 | 0.93 | -13.81% |
| 2016 | 1.08 | -61.46% |
| 2015 | 2.79 | 192.12% |
| 2014 | 0.96 | -53.11% |
| 2013 | 2.04 | 34.88% |
| 2012 | 1.51 | 42.73% |
| 2011 | 1.06 | -15.01% |
| 2010 | 1.25 | 40.84% |
| 2009 | 0.89 | -26.97% |
| 2008 | 1.21 | 33.07% |
| 2007 | 0.91 | 31.45% |
| 2006 | 0.69 | -80.59% |
| 2005 | 3.57 | 0.00% |
P/B arány hasonló vállalatoknál vagy versenytársaknál
| Vállalat | P/B arány | P/B arány különbség | Ország |
|---|---|---|---|
| 6.251 | -85.10% |
US
|
|
| 13.2547 | -68.41% |
US
|
|
| 4.208 | -89.97% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -85.27% |
NL
|
